A Peptide Derived from IKK-Interacting Protein Attenuates NF-κB Activation and Inflammation

  • J Immunol. 2021 Sep 15;207(6):1652-1661. doi: 10.4049/jimmunol.2100397.
Hansen Liu  1 Zhenzhen Yan  1 Yunpeng Zhao  2 Xiaoyuan Ma  2 Honghai Zhang  1 Xueer Wang  1 Wanxin Zhuang  1 Yi Zheng  1 Bingyu Liu  1 Lei Zhang  3 Chengjiang Gao  3
Affiliations
  • 1. Key Laboratory of Infection and Immunity of Shandong Province and Department of Immunology, School of Biomedical Sciences, Shandong University, Jinan, Shandong, People's Republic of China; and.
  • 2. Department of Orthopedics, Qilu Hospital Cheelow Medical School, Shandong University, Jinan, Shandong, People's Republic of China.
  • 3. Key Laboratory of Infection and Immunity of Shandong Province and Department of Immunology, School of Biomedical Sciences, Shandong University, Jinan, Shandong, People's Republic of China; and [email protected] [email protected].
Abstract

The IκB kinase (IKK) complex plays a vital role in regulating the NF-κB activation. Aberrant NF-κB activation is involved in various inflammatory diseases. Thus, targeting IKK activation is an ideal therapeutic strategy to cure and prevent inflammatory diseases related to NF-κB activation. In a previous study, we demonstrated that IKK-interacting protein (IKIP) inhibits the phosphorylation of IKKα/β and the activation of NF-κB through disruption of the formation of IKK complex. In this study, we identified a 15-aa peptide derived from mouse IKIP (46-60 aa of IKIP), which specifically suppressed IKK activation and NF-κB targeted gene expression via disrupting the association of IKKβ and NEMO. Importantly, administration of the peptide reduced LPS-induced acute inflammation and attenuated Zymosan-induced acute arthritis in mice. These findings suggest that this IKIP peptide may be a promising therapeutic reagent in the prevention and treatment of inflammatory diseases.

Products
Inhibitors & Agonists
Other Products